Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 5/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150447 | 1.00 | CCR3 (0.34) | CCR3SIGMAR1HTR2CNR1I2PRKCA | |
| SCHEMBL4156129 | 0.94 | CNR2 (0.38) | CCR3NR1I2PRKCAMMP12NAMPT | |
| SCHEMBL4156124 | 0.94 | CNR2 (0.38) | CCR3NR1I2PRKCAMMP12NAMPT | |
| SCHEMBL4153105 | 0.93 | CCR3 (0.34) | CCR3SIGMAR1NR1I2PRKCAMMP12 | |
| SCHEMBL4153108 | 0.93 | CCR3 (0.34) | CCR3SIGMAR1NR1I2PRKCAMMP12 | |
| SCHEMBL4152321 | 0.91 | KCNH2 (0.35) | SIGMAR1HTR2CPRKCAMMP12HTR1A | |
| SCHEMBL4152317 | 0.91 | KCNH2 (0.35) | SIGMAR1HTR2CPRKCAMMP12HTR1A | |
| SCHEMBL4140597 | 0.91 | PRKCA (0.40) | CCR3HTR2CNR1I2PRKCAMMP12 | |
| SCHEMBL4140592 | 0.91 | PRKCA (0.40) | CCR3HTR2CNR1I2PRKCAMMP12 | |
| SCHEMBL4157786 | 0.90 | PRKCA (0.38) | SIGMAR1PRKCAMMP12HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-05-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | IDO1, IDO2, ZC3HAV1 | CCR3 135/4885SIGMAR1 883/4885HTR2C 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.